ATE391774T1 - Verwendung von bakterien mit arginin- deiminaseaktivität zur induktion der apoptose und/oder zur hemmung einer entzündungsreaktion, und diese enthaltende pharmazeutische oder diätetische zusammensetzungen - Google Patents

Verwendung von bakterien mit arginin- deiminaseaktivität zur induktion der apoptose und/oder zur hemmung einer entzündungsreaktion, und diese enthaltende pharmazeutische oder diätetische zusammensetzungen

Info

Publication number
ATE391774T1
ATE391774T1 AT98950301T AT98950301T ATE391774T1 AT E391774 T1 ATE391774 T1 AT E391774T1 AT 98950301 T AT98950301 T AT 98950301T AT 98950301 T AT98950301 T AT 98950301T AT E391774 T1 ATE391774 T1 AT E391774T1
Authority
AT
Austria
Prior art keywords
inhibiting
bacteria
pharmaceutical
compositions containing
same
Prior art date
Application number
AT98950301T
Other languages
English (en)
Inventor
Simone Claudio De
Original Assignee
Actial Farmaceutica Lda
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Actial Farmaceutica Lda filed Critical Actial Farmaceutica Lda
Application granted granted Critical
Publication of ATE391774T1 publication Critical patent/ATE391774T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C12N1/205—Bacterial isolates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/78—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • C12R2001/225—Lactobacillus
    • C12R2001/24—Lactobacillus brevis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT98950301T 1998-02-20 1998-10-13 Verwendung von bakterien mit arginin- deiminaseaktivität zur induktion der apoptose und/oder zur hemmung einer entzündungsreaktion, und diese enthaltende pharmazeutische oder diätetische zusammensetzungen ATE391774T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IT98RM000103A IT1298918B1 (it) 1998-02-20 1998-02-20 Uso di batteri dotati di arginina deiminasi per indurre apoptosi e/o ridurre una reazione infiammatoria e composizioni farmaceutiche

Publications (1)

Publication Number Publication Date
ATE391774T1 true ATE391774T1 (de) 2008-04-15

Family

ID=11405583

Family Applications (1)

Application Number Title Priority Date Filing Date
AT98950301T ATE391774T1 (de) 1998-02-20 1998-10-13 Verwendung von bakterien mit arginin- deiminaseaktivität zur induktion der apoptose und/oder zur hemmung einer entzündungsreaktion, und diese enthaltende pharmazeutische oder diätetische zusammensetzungen

Country Status (25)

Country Link
US (2) US6572854B1 (de)
EP (1) EP1058725B1 (de)
JP (1) JP4253439B2 (de)
KR (1) KR100594569B1 (de)
CN (1) CN1189560C (de)
AR (2) AR020053A1 (de)
AT (1) ATE391774T1 (de)
AU (1) AU754483B2 (de)
BR (1) BR9815677A (de)
CA (1) CA2321263C (de)
CY (1) CY1108112T1 (de)
DE (1) DE69839351T2 (de)
DK (1) DK1058725T3 (de)
EA (1) EA006018B1 (de)
ES (1) ES2303357T3 (de)
HK (1) HK1033338A1 (de)
IL (1) IL137799A (de)
IN (2) IN188450B (de)
IT (1) IT1298918B1 (de)
MX (1) MX237377B (de)
PT (1) PT1058725E (de)
SI (1) SI1058725T1 (de)
TR (1) TR200002326T2 (de)
WO (1) WO1999042568A1 (de)
ZA (1) ZA9811619B (de)

Families Citing this family (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1296148B1 (it) * 1996-11-22 1999-06-09 Renata Maria Anna Ve Cavaliere Uso di batteri lattici per accrescere il livello delle ceramidi della pelle e delle mucose, e composizioni dermatologiche e cosmetiche atte
IT1311495B1 (it) * 1999-06-09 2002-03-13 Mendes S U R L Composizione comprendente sfingomielinasi alcalina, utilizzabile qualeprodotto dietetico, integratore alimentare o medicamento.
US8697051B2 (en) * 1999-06-09 2014-04-15 Vsl Pharmaceuticals Inc. Composition comprising alkaline sphingomyelinase for use as a dietetic preparation, food supplement or pharmaceutical product
IT1306716B1 (it) * 1999-06-21 2001-10-02 Mendes S U R L Associazione di batteri lattici e suo uso per la prevenzione e/o iltrattamento terapeutico di infezioni e di stati infiammatori.
AUPQ415899A0 (en) * 1999-11-19 1999-12-16 Vasse Research Institute Pty Ltd Compositions for and methods of treatment of allergic diseases
HU227086B1 (en) * 1999-11-25 2010-06-28 Vakcina Kft Lactobacillus vaccine for treating prostata inflammatory and benign prostata hyperplasia
FR2809312B1 (fr) * 2000-05-25 2002-07-12 Gervais Danone Sa Utilisation de l. casei dans des compositions immunostimulantes
US6767537B2 (en) * 2000-05-26 2004-07-27 Phil Arnold Nicolay Composition and method for the treatment of sinusitis
CA2457092A1 (en) * 2001-09-05 2003-03-20 Vsl Pharmaceuticals, Inc. Lactic acid bacteria comprising unmethylated cytosine-guanine dinucleotides for use in therapy
ITRM20010763A1 (it) * 2001-12-21 2003-06-21 Simone Claudio De Nuovo ceppo di batterio lattico e composizioni commestibili, farmaci e prodotti veterinari che lo contengono.
EP1599217B1 (de) * 2002-11-18 2014-04-16 Polaris Group Verfahren zur verhinderung von virusreplikation in vivo
US8877178B2 (en) 2003-12-19 2014-11-04 The Iams Company Methods of use of probiotic bifidobacteria for companion animals
US20050158294A1 (en) 2003-12-19 2005-07-21 The Procter & Gamble Company Canine probiotic Bifidobacteria pseudolongum
TW200700074A (en) * 2005-03-04 2007-01-01 Calpis Co Ltd Inducer of t cell apoptosis
JP4938005B2 (ja) 2005-05-31 2012-05-23 ザ・アイムス・カンパニー ネコ科動物プロバイオティックであるラクトバシラス
JP4938006B2 (ja) 2005-05-31 2012-05-23 ザ・アイムス・カンパニー ネコ科動物プロバイオティク・ビフィドバクテリア
EA016734B1 (ru) 2006-12-21 2012-07-30 Калпис Ко., Лтд. СРЕДСТВА ДЛЯ СТИМУЛЯЦИИ ПРОДУЦИРОВАНИЯ IgA НА ОСНОВЕ БАКТЕРИЙ LACTOBACILLUS AMYLOVORUS И ШТАММ БАКТЕРИЙ LACTOBACILLUS AMYLOVORUS CP1750 FERM BP-10532
CN100584940C (zh) * 2007-05-17 2010-01-27 江南大学 一株产精氨酸脱亚氨酶的菌种及其应用
JP5247120B2 (ja) * 2007-11-02 2013-07-24 雪印メグミルク株式会社 Ｌ−オルニチン含有物の製造方法
EE05341B1 (et) * 2008-05-13 2010-08-16 O� Tervisliku Piima Biotehnoloogiate Arenduskeskus Isoleeritud mikroorganismi tvi Lactobacillus plantarum Inducia DSM 21379 kui organismi loomulikku kaitsev?imet t?stev probiootik, seda sisaldav toiduaine ja kompositsioon ning mikroorganismi kasutamine rakulist immuunsust t?stva ravimi valmistamisek
US9771199B2 (en) 2008-07-07 2017-09-26 Mars, Incorporated Probiotic supplement, process for making, and packaging
CN101606952B (zh) * 2008-06-17 2012-09-19 上海交通大学医学院附属第三人民医院 乳双歧杆菌在制备预防泌尿系统结石药物中的应用
JP5526320B2 (ja) * 2008-09-04 2014-06-18 国立大学法人旭川医科大学 腸管保護剤
US10104903B2 (en) 2009-07-31 2018-10-23 Mars, Incorporated Animal food and its appearance
CN102548565A (zh) * 2009-10-22 2012-07-04 株式会社益力多本社 癌症发病风险降低剂
JP5660508B2 (ja) * 2010-04-08 2015-01-28 国立大学法人旭川医科大学 腸管保護剤
KR101062779B1 (ko) 2010-04-28 2011-09-06 삼육대학교산학협력단 충치 유발 세균의 성장 억제 활성을 나타내는 비피도박테리움 아돌레센티스 ｓｐｍ1005 균주 및 상기 비피도박테리움 아돌레센티스 ｓｐｍ1005 균주 또는 이의 배양물을 유효 성분으로 하는 충치 예방용 식품 및 약제학 조성물
GB201112091D0 (en) 2011-07-14 2011-08-31 Gt Biolog Ltd Bacterial strains isolated from pigs
GB201117313D0 (en) 2011-10-07 2011-11-16 Gt Biolog Ltd Bacterium for use in medicine
CN102433290B (zh) * 2012-01-16 2013-06-12 江南大学 一株产瓜氨酸的菌株及用该菌株生物合成瓜氨酸的方法
TW201611843A (en) 2012-04-04 2016-04-01 Polaris Group Methods of treatment with arginine deiminase
ES2805360T3 (es) 2013-03-15 2021-02-11 Tdw Group Arginina desiminasa con reactividad cruzada reducida hacia anticuerpos para ADI - PEG 20 para el tratamiento del cáncer
GB201306536D0 (en) 2013-04-10 2013-05-22 Gt Biolog Ltd Polypeptide and immune modulation
WO2015111597A1 (ja) * 2014-01-22 2015-07-30 株式会社明治 シトルリンの調製方法
KR102353046B1 (ko) 2014-03-18 2022-01-19 티디더블유 그룹 조작된 키메라성 페길화된 ａｄｉ 및 사용 방법
TWI775160B (zh) 2014-09-16 2022-08-21 開曼群島商瑞華藥業集團 用於治療癌症之與adi-peg 20抗體具有降低之交叉反應性的精胺酸脫亞胺酶
SI3065748T1 (en) 2014-12-23 2018-05-31 4D Pharma Research Limited Severe bacteroid tethethioomycron and its use in reducing inflammation
JP6427278B2 (ja) 2014-12-23 2018-11-21 フォーディー ファーマ リサーチ リミテッド４Ｄ Ｐｈａｒｍａ Ｒｅｓｅａｒｃｈ Ｌｉｍｉｔｅｄ ｐｉｒｉｎポリペプチド及び免疫モジュレーション
MA41010B1 (fr) 2015-06-15 2020-01-31 4D Pharma Res Ltd Compositions comprenant des souches bactériennes
MA41060B1 (fr) 2015-06-15 2019-11-29 4D Pharma Res Ltd Compositions comprenant des souches bactériennes
RS59446B1 (sr) 2015-06-15 2019-11-29 4D Pharma Res Ltd Blautia stercosis i wexlerae za upotrebu u lečenju inflamatornih i autoimunskih bolesti
SI3360559T1 (sl) 2015-06-15 2020-02-28 4D Pharma Research Limited Sestavki, ki vsebujejo bakterijske seve
CN114984057A (zh) 2015-06-15 2022-09-02 4D制药研究有限公司 包含细菌菌株的组合物
EP3209310B1 (de) 2015-11-20 2018-01-31 4D Pharma Research Limited Zusammensetzungen mit bakterienstämmen
GB201520497D0 (en) 2015-11-20 2016-01-06 4D Pharma Res Ltd Compositions comprising bacterial strains
GB201520638D0 (en) 2015-11-23 2016-01-06 4D Pharma Res Ltd Compositions comprising bacterial strains
GB201520631D0 (en) 2015-11-23 2016-01-06 4D Pharma Res Ltd Compositions comprising bacterial strains
CN106994134B (zh) * 2016-01-25 2020-08-25 深圳华大生命科学研究院 肠道益生菌在预防和/或治疗糖尿病及其相关疾病中的应用
GB201612191D0 (en) 2016-07-13 2016-08-24 4D Pharma Plc Compositions comprising bacterial strains
NZ745678A (en) 2016-03-04 2019-03-29 4D Pharma Plc Compositions comprising bacterial blautia strains for treating visceral hypersensitivity
TW201821093A (zh) 2016-07-13 2018-06-16 英商４Ｄ製藥有限公司 包含細菌菌株之組合物
GB201621123D0 (en) 2016-12-12 2017-01-25 4D Pharma Plc Compositions comprising bacterial strains
US11179426B2 (en) * 2016-12-29 2021-11-23 Kibow Biotech, Inc. Composition and method for maintaining healthy kidney function
CN108265068B (zh) * 2016-12-31 2021-06-15 江苏众红生物工程创药研究院有限公司 重组精氨酸脱亚胺酶及其产业化制备方法和应用
AU2018272291A1 (en) 2017-05-22 2020-01-16 4D Pharma Research Limited Compositions comprising bacterial strains
TW201907931A (zh) 2017-05-24 2019-03-01 英商4D製藥研究有限公司 包含細菌菌株之組合物
CN111107859B (zh) 2017-06-14 2022-04-29 4D制药研究有限公司 包含细菌菌株的组合物
HUE052319T2 (hu) 2017-06-14 2021-04-28 4D Pharma Res Ltd Baktériumtörzseket tartalmazó készítmények
ES2917415T3 (es) 2017-06-14 2022-07-08 4D Pharma Res Ltd Composiciones que comprenden una cepa bacteriana
RU2675110C1 (ru) * 2018-04-09 2018-12-17 Федеральное государственное бюджетное учреждение науки Институт общей генетики им. Н.И. Вавилова Российской академии наук (ИОГЕН РАН) Фармацевтическая композиция для терапии воспалительных заболеваний слизистых оболочек кишечника на основе штамма Lactobacillus brevis 47f, проявляющая местную противовоспалительную активность
FR3082207B1 (fr) 2018-06-06 2022-03-25 Agronomique Inst Nat Rech Nouvelle souche probiotique de lactobacillus brevis
KR102069622B1 (ko) * 2019-06-25 2020-01-23 한국식품연구원 락토바실러스 퍼멘텀 WiKim0102를 유효성분으로 포함하는 암의 예방 또는 치료용 약학 조성물
JPWO2021261423A1 (de) * 2020-06-22 2021-12-30
KR102363111B1 (ko) * 2021-06-29 2022-02-15 (주)바이오일레븐 항염 및 항산화 활성을 갖는 락토바실러스 퍼멘텀 균주 및 이의 용도

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4415550A (en) * 1983-03-04 1983-11-15 Pakhomov Gennady N Treatment-and-prophylactic tooth paste possessing anticarious effect
JP2900279B2 (ja) 1989-08-02 1999-06-02 株式会社ジャパンエナジー 新規なアルギニンデイミナーゼ、その製造法及び該酵素を有効成分とする制癌剤
US5196195A (en) * 1990-03-27 1993-03-23 Cornell Research Foundation, Inc. Use of arginase to control nitric oxide formation
GB9107305D0 (en) 1991-04-08 1991-05-22 Unilever Plc Probiotic
AUPM596894A0 (en) 1994-05-30 1994-06-23 Hybrid Scientific Pty Ltd Composition for treating gastrointestinal disorders - a combination of bismuth salts plus lactobacillus or bifidobacteria species bacteria for treating gastrointestinal disorders
US5599795A (en) * 1994-08-19 1997-02-04 Mccann; Michael Method for treatment of idiopathic inflammatory bowel disease (IIBD)

Also Published As

Publication number Publication date
AR020053A1 (es) 2002-04-10
AU754483B2 (en) 2002-11-14
EA200000856A1 (ru) 2001-02-26
TR200002326T2 (tr) 2000-11-21
BR9815677A (pt) 2000-10-24
ITRM980103A0 (it) 1998-02-20
WO1999042568A1 (en) 1999-08-26
IL137799A (en) 2005-08-31
US7147847B2 (en) 2006-12-12
DE69839351T2 (de) 2009-06-25
JP4253439B2 (ja) 2009-04-15
KR20010106092A (ko) 2001-11-29
JP2002504324A (ja) 2002-02-12
IN188450B (de) 2002-09-28
DE69839351D1 (de) 2008-05-21
SI1058725T1 (sl) 2008-08-31
HK1033338A1 (en) 2001-08-24
ITRM980103A1 (it) 1999-08-20
EA006018B1 (ru) 2005-08-25
DK1058725T3 (da) 2008-08-18
CA2321263C (en) 2009-08-11
US6572854B1 (en) 2003-06-03
AU9644198A (en) 1999-09-06
MXPA00007990A (es) 2001-03-01
CN1284994A (zh) 2001-02-21
EP1058725A1 (de) 2000-12-13
US20030215429A1 (en) 2003-11-20
IN1999KO00116A (de) 2005-03-11
KR100594569B1 (ko) 2006-06-30
CY1108112T1 (el) 2014-02-12
IL137799A0 (en) 2001-10-31
ZA9811619B (en) 1999-06-23
MX237377B (es) 2006-05-31
EP1058725B1 (de) 2008-04-09
CA2321263A1 (en) 1999-08-26
ES2303357T3 (es) 2008-08-01
PT1058725E (pt) 2008-06-19
CN1189560C (zh) 2005-02-16
AR071841A2 (es) 2010-07-21
IT1298918B1 (it) 2000-02-07

Similar Documents

Publication Publication Date Title
ATE391774T1 (de) Verwendung von bakterien mit arginin- deiminaseaktivität zur induktion der apoptose und/oder zur hemmung einer entzündungsreaktion, und diese enthaltende pharmazeutische oder diätetische zusammensetzungen
EE200100659A (et) Diaminotiasoolid ja nende kasutamine proteiinikinaaside pärssimiseks
DE69900249D1 (de) Pharmazeutische zusammensetzung von metformin und fibrat, und ihre verwendung zur behandlung von hyperglykämie
DE69729646D1 (de) Formulierung zur verwendung in der vorbeugung von pathogen-induzierten erkrankungen, einschliesslich hiv und hsv
ATE277196T1 (de) Messung und kontrolle von sessiler und planktonischer mikrobiologischer aktivität in industriellen wassersystemen
DE60313996D1 (de) Aryloxyphenoxypropionate und safener enthaltende mittel und deren verwendung zur erhöhung der unkrautbekämpfung
DE69941566D1 (de) N-acetylhomotaurinate zur verwendung in der behandlung von hyperkinesie
ATE262892T1 (de) Verwendung einer zusammensetzung enthaltend capsaicin oder resiniferatoxin zur behandlung des reizdarmsyndroms
EE200100717A (et) Indasooliühendid ja farmatseutilised kompositsioonid proteiini kinaaside inhibeerimiseks ja meetodid nende kasutamiseks
DE69729284D1 (de) Filmbildende zusammensetzungen von antihyperalgesischen opiaten und deren verwendung zur behandlung von hyperalgesie
EE03904B1 (et) Graanul, farmatseutiline doseerimisvorm, graanulite valmistamismeetod ja ravimiga kaetud graanulid
NO20063000L (no) Kombinasjon og farmasøytisk blanding for behandling av diabetes samt anvendelse derav.
ATE247967T1 (de) Pharmazeutische kombination mit einem trizyclischen komponent und mindestens einem aus zolpidem, zopiclone und brotizolam, zur behandlung von schlafstörungen
DE3683318D1 (de) Verwendung von alfuzosin zur behandlung von erkrankungen der harnwege.
DE69212620D1 (de) Verwendung von Glycosaminoglycanen zur Behandlung von diabetischer Nephropathie und diabetischer Neuropathie
EE200100391A (et) Peptidüül-heterotsüklilised ketoonid, nende kasutamine ja farmatseutiline kompositsioon
NO990433D0 (no) Nye forbindelser og blandinger for behandling av sykdommer i forbindelse med tryptase-aktivitet
DE69931799D1 (de) Absorptionsbeschleuniger und diese enthaltende zubereitungen zur transdermalen absorption
GB0427241D0 (en) Napthalene derivatives which inhibit the cytokine or biological activity of macrophage migration inhibitory factor (MIF)
DE3667605D1 (de) Windel zur verhuetung von wundliegen.
DE3879811D1 (de) Pharmazeutische zusammensetzung und ihre verwendung.
DE69914951D1 (de) Substituierte tricyclische Verbindungen und deren Verwendung zur Behandlung von sPLA2-bedingten Erkrankungen
DE3688369D1 (de) Nodulationsfoerdernde bakterien und ihre verwendung.
DE69939075D1 (de) Pharmazeutische Zusammenstellung zur Vorbeugung und Behandlung von mit Zellkrankheiten des Augenhintergrundes zusammenhängenden Krankheiten
NO20012106D0 (no) Middel for behandling av benpatobolisme

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1058725

Country of ref document: EP